Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of Everolimus in Combination With Exemestane in Postmenopausal Patients With Hormone Receptor-positive, HER 2-negative Advanced Breast Cancer

NCT02023359 is registered in ClinicalTrials.gov with Novartis Healthcare A/S as lead sponsor.

NCT NCT02023359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02023359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of Everolimus in Combination With Exemestane in Postmenopausal Patients With Hormone Receptor-positive, HER 2-negative Advanced Breast Cancer
Lead sponsor
Novartis Healthcare A/S
Phase
Observational
Overall status
Completed
Start date
December 31, 2013
Completion date
April 30, 2015
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer